Trial Profile
Phase 3, Prospective, Randomized, Multi-center Clinical Study Comparing the Safety and Efficacy of BAX 855 Following PK-guided Prophylaxis Targeting Two Different FVIII Trough Levels in Subjects With Severe Hemophilia A
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Rurioctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Registrational; Therapeutic Use
- Acronyms PROPEL
- Sponsors Baxalta; Shire
- 31 Oct 2023 According to Octapharma media release, data from the study were presented in the European Journal of Haematology.
- 31 Oct 2023 Results of Indirect comparison from a matching-adjusted indirect comparison (MAIC) of Nuwiq (simoctocog alfa) versus extended half-life recombinant factor VIII (rFVIII) concentrates in haemophilia A patients undergoing personalised prophylaxis published in the Media Release
- 15 Sep 2023 Results of secondary analysis evaluating collagen turnover biomarkers as an objective measure for efficacy of treatment with rurioctocog alfa pegol in Hemophilia A patients, published in the Journal of Thrombosis and Haemostasis